Rachelle Johnson

Dr. Rachelle Johnson

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2017 in Current Osteoporosis Reports
Verified
Journal Article
Closed access
PDF file
RJRachelle Johnson
Rachelle Johnson
MSMiranda E. Sowder
Miranda E. Sowder
AGAmato J. Giaccia
Amato J. Giaccia

3 December 2018 in JBMR Plus
Verified
Journal Article
Open access
PDF file
MSMiranda E Sowder
Miranda E Sowder
RJRachelle Johnson
Rachelle Johnson
Bone marrow provides a unique microenvironment favoring the colonization and outgrowth of metastatic tumor cells. Despite the high incidence of bone metastasis in breast and prostate cancer patients, many of the molecular mechanisms controlling metastatic progression remain unclear. Several gene signatures associated with bone metastasis have been reported, but no metastasis‐specific gene alterations have been identified. Therefore, there has been considerable interest in understanding how the bone microenvironment impacts the behavior of disseminated tumor cells (DTCs) prior to and following colonization of the bone. Substantial evidence indicates that disruption of normal bone homeostasis by tumor‐derived factors establishes a premetastatic niche within the bone that favors DTC colonization. Following dissemination, bone resident cells and the surrounding stroma provide critical signals that support tumor cell colonization, survival, and eventual outgrowth. Clinical data suggest that patients can harbor DTCs for years to decades prior to developing overt bone metastases, suggesting a period of tumor dormancy occurs in the bone marrow. Several dormancy‐promoting factors have been recently identified; however, critical questions surrounding the molecular triggers and timing of tumor cell emergence from dormancy remain. Here, we review how metastatic tumor cells co‐opt the bone marrow microenvironment for metastatic progression and discuss emerging insights into how to more effectively target DTCs and prevent metastasis. © 2018 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research

30 September 2023 in Journal of Bone Oncology
Verified
Journal Article
Open access
GJGwenyth J. Joseph
Gwenyth J. Joseph
DJDouglas B. Johnson
Douglas B. Johnson
RJRachelle Johnson
Rachelle Johnson
• Patients with bone metastases have comparably poorer survival in response to immune checkpoint inhibitors (ICIs) compared to patients without bone metastases. • Co-administration of ICIs with bone-targeted agents improve outcomes in patients with bone metastasis. • Fracture risk is elevated in patients treated with ICIs, regardless of whether they have bone metastatic disease. • There are limited pre-clinical studies investigating osteoimmunology in the tumor-bone microenvironment, but myeloid cells and CD4+ and especially CD8+ T cells are likely to play a role in bone metastatic progression.

1 October 2020 in Cancer Letters
Verified
Journal Article
Closed access
VTVera M. Todd
Vera M. Todd
RJRachelle Johnson
Rachelle Johnson

14 November 2017 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
RJRachelle Johnson
Rachelle Johnson
LSLarry John Suva
Larry John Suva

10 July 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
MCMiranda E. Clements
Miranda E. Clements
LHLauren Holtslander
Lauren Holtslander
CECourtney Edwards
Courtney Edwards
VTVera Todd
Vera Todd
SDSamuel D. R. Dooyema
Samuel D. R. Dooyema
RJRachelle Johnson
Rachelle Johnson